113. Muscular dystrophy Clinical trials / Disease details


Clinical trials : 646 Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

  
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003563-22-IE
(EUCTR)
23/06/202021/01/2020A study to provide Edasalonexent to Pediatric Patients with Duchenne Muscular DystrophyAn Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Edasalonexent
Product Code: CAT-1004
INN or Proposed INN: EDASALONEXENT
Catabasis Pharmaceuticals Inc.NULLNot RecruitingFemale: no
Male: yes
140Phase 3United States;Canada;Ireland;Australia;Germany;United Kingdom;Sweden
2EUCTR2019-003563-22-GB
(EUCTR)
23/04/202013/01/2020A study to provide Edasalonexent to Pediatric Patients with Duchenne Muscular DystrophyAn Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy - An Open-Label Extension Study of Edasalonexent in DMD Patients Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Edasalonexent
Product Code: CAT-1004
INN or Proposed INN: EDASALONEXENT
Catabasis Pharmaceuticals Inc.NULLNot RecruitingFemale: no
Male: yes
140Phase 3United States;Canada;Ireland;Australia;Germany;United Kingdom;Sweden
3EUCTR2019-003563-22-DE
(EUCTR)
16/04/202031/01/2020A study to provide Edasalonexent to Pediatric Patients with Duchenne Muscular DystrophyAn Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Edasalonexent
Product Code: CAT-1004
INN or Proposed INN: EDASALONEXENT
Catabasis Pharmaceuticals Inc.NULLNot RecruitingFemale: no
Male: yes
140Phase 3United States;Canada;Ireland;Australia;Israel;Germany;United Kingdom;Sweden
4EUCTR2019-003563-22-SE
(EUCTR)
15/04/202003/02/2020A study to provide Edasalonexent to Pediatric Patients with Duchenne Muscular DystrophyAn Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Edasalonexent
Product Code: CAT-1004
INN or Proposed INN: EDASALONEXENT
Catabasis Pharmaceuticals Inc.NULLNot RecruitingFemale: no
Male: yes
140Phase 3United States;Canada;Ireland;Australia;Germany;United Kingdom;Sweden
5EUCTR2018-000464-29-DE
(EUCTR)
31/01/201924/09/2018A study to compare edasalonexent with placebo in patients with Duchenne Muscular dystrophyA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL PHASE 3 STUDY OF EDASALONEXENT IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY - POLARIS DMD Duchenne muscular dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Edasalonexent
Product Code: CAT-1004
INN or Proposed INN: EDASALONEXENT
Product Name: Edasalonexent
Product Code: CAT-1004
INN or Proposed INN: EDASALONEXENT
Catabasis Pharmaceuticals, Inc.NULLNot RecruitingFemale: no
Male: yes
126Phase 3United States;Canada;Ireland;Australia;Israel;Germany;United Kingdom;Sweden
6EUCTR2018-000464-29-IE
(EUCTR)
16/01/201902/10/2018A study to compare edasalonexent with placebo in pediatric patients with Duchenne Muscular dystrophy.A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, GLOBAL PHASE 3 STUDY OFEDASALONEXENT IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY - Phase 3 Study of Edasalonexent in Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Edasalonexent
Product Code: CAT-1004
INN or Proposed INN: Edasalonexent
Catabasis Pharmaceuticals, Inc.NULLNot RecruitingFemale: no
Male: yes
126Phase 3United States;Canada;Ireland;Australia;Israel;Germany;United Kingdom;Sweden
7EUCTR2018-000464-29-SE
(EUCTR)
11/12/201824/09/2018A study to compare edasalonexent with placebo in patients with Duchenne Muscular dystrophy.A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, GLOBAL PHASE 3 STUDY OFEDASALONEXENT IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY - POLARIS DMD Duchenne Muscular Dystrophy
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Product Name: Edasalonexent
Product Code: CAT-1004
INN or Proposed INN: Edasalonexent
Catabasis Pharmaceuticals, Inc.NULLNot RecruitingFemale: no
Male: yes
126Phase 3Canada;Ireland;Australia;Israel;Germany;United Kingdom;Sweden;United States
8NCT02439216
(ClinicalTrials.gov)
April 201629/4/2015Phase 1/2 Study in Boys With Duchenne Muscular DystrophyA Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular DystrophyMuscular Dystrophy, DuchenneDrug: Edasalonexent;Drug: PlaceboCatabasis PharmaceuticalsNULLCompleted4 Years7 YearsMale31Phase 1/Phase 2United States